ProStrakan to receive $10 million upfront for testosterone product

The UK specialty pharmaceutical company, ProStrakan Group Plc, is to receive $10 million upfront in an exclusive licensing and distribution deal with Endo Pharmaceuticals Inc for its testosterone replacement therapy, Fortesta.